Podcasts about Heart failure

Cancer rise in younger adults may be explained by accelerated cellular aging; “Quadriceps activation failure” may explain common waking difficulty following successful knee replacement; Is “Calocurb” a good natural alternative to GLP-1 drugs? New study claims 4 to 6 servings of whole grains may be the key to heart health—but doubts arise due to its authorship in Iran, a hotbed of scientific research fraud; Splenda back in the crosshairs as new evidence points to genetic damage; Bright lights at night emerge as new heart disease risk factor. 

A second ESC recap plus two breaking stories on the failure of an investigational Lp(a) reducing drug and a new FDA approval of an AI-ECG app are covered by John Mandrola, MD This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Lp(a) Disappointment HORIZON https://clinicaltrials.gov/study/NCT04023552 Press Release https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd Rationale paper https://doi.org/10.1016/j.ahj.2025.03.019 II FDA Clears AI-ECG for Acute MI Detection  Accuracy of cath lab activation decisions for STEMI-equivalent and mimic ECGs: Physicians vs. AI (Queen of Hearts by PMcardio) 10.1016/j.ajem.2025.07.061 AI-Enabled ECG Analysis Improves Diagnostic Accuracy and Reduces False STEMI Activations: A Multicenter U.S. Registry https://www.jacc.org/doi/10.1016/j.jcin.2025.10.018 Queen of Hearts™ AI ECG App https://www.powerfulmedical.com/pmcardio-stemi/ III TARGET CTCA Trial Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain https://www.nejm.org/doi/10.1056/NEJMoa2608903 IV CorCal trial Press release https://www.escardio.org/news/press/press-releases/new-data-presented-on-the-use-of-coronary-artery-calcium-for-cardiovascular-risk-assessment/ CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics https://doi.org/10.1016/j.ahj.2026.107473 V AMUNDSEN Trial LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial InfarctionThe AMUNDSEN Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2853274 VI TRIC-I-HF trial Tricuspid Repair Cuts Death, HF Hospitalization in Severe TR https://www.medscape.com/viewarticle/tricuspid-repair-cuts-death-hf-hospitalization-severe-tr-2026a1000wvk Tricuspid-Valve Intervention in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2606934 You May Also Like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington  Questions or feedback, please contact news@medscape.net

Dr. Jared Rutter, PhD, Professor of Biochemistry at the University of Utah and Howard Hughes Medical Institute Investigator, is a leading expert on mitochondria and metabolism. He explains how mitochondria produce the energy for your cells to work but also how they regulate cell growth and replication and thereby contribute to health and disease. We also discuss how mitochondria are linked to aging, cancer, and other diseases. Our conversation explores your metabolism as the composite of trillions of individual cells and points to new ways to improve health, avoid, and treat diseases. Show notes: https://go.hubermanlab.com/297-jared-rutter Pre-order Protocols: https://protocolsbook.com Thank you to our sponsors AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman BetterHelp: https://betterhelp.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Jared Rutter (00:02:29) Metabolism, Cells; Aging (00:08:36) Mitochondria, Origin & Cell Complexity (00:13:07) Sponsors: Joovv & BetterHelp (00:15:16) Mitochondria Genome, Inheritance (00:18:18) Mitochondria & Spatial Distribution; Cell-Specific Metabolism (00:25:59) Nutrient Energy, Hormones, Fat Cells (00:31:13) Glucose, ATP Conversion, Pyruvate (00:36:41) Cell Choice: Energy or Growth, Cancer; Virus (00:46:02) Sponsors: AG1 & Eight Sleep (00:48:36) Microbiome, Role of Humans (00:51:44) Molecule Discovery Process, MPC1, MPC2 (00:59:42) Cell Resource Sensing, Fasting, Glucagon, Fat Cells; Neurons, Heart (01:07:03) Cell Resource Allocation, MPC, Heart Failure; Disease (01:11:46) Sponsor: Function (01:13:24) Cell Size vs Fuel Balance, Cell Identity & Disease (01:20:43) MPC Discovery, Genetics, Model Systems (01:24:29) Lactate, Oxygen, Exercise; Energy Prioritization Hierarchy (01:31:32) Cancer, Mutations, Metabolism Changes & Warburg Effect (01:36:18) Cancer Challenges & Therapies (01:43:00) Therapy Combinations, Unique Cancer Mutations & Metabolism (01:48:31) Technology to Visualize Metabolism; Disease, Metabolism & Scents (01:56:34) Excess Energy & Mitochondria, Reactive Oxygen Species (02:01:12) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

High cholesterol can start damaging your arteries long before you feel anything — and your total cholesterol number does not tell the whole story. So when should you start checking it, what do LDL and other cholesterol particles really mean, and when are lifestyle changes no longer enough?In this episode of Baptist Health Talk, host Dr. Anthony Gonzalez speaks with Dr. Sanjeev Gulati about how cholesterol contributes to heart attacks and heart failure, why screening should begin earlier than many people think, and the treatment options available today. Why high cholesterol is directly linked to heart attack risk  Common cholesterol myths, including the idea that diet is the only cause  How LDL and lipoprotein(a) contribute to plaque buildup and inflammation  How uncontrolled cholesterol can ultimately contribute to heart failure  Why cholesterol screening may need to begin in your 20s  How family history and familial hypercholesterolemia change cardiovascular risk  Lifestyle steps that can help lower cholesterol  When cholesterol-lowering medication may be needed  Why cholesterol control remains critical even after a heart attack  How advanced lipid testing can provide a clearer picture of individual riskHost:Anthony Gonzalez, M.D.Chief of Surgery, Baptist Health Baptist HospitalMedical Director of Bariatric Surgery, Baptist HealthGuest:Sanjeev Kumar Gulati, M.D., Executive Deputy DirectorSystem Chief of Cardiovascular MedicineBaptist Health Heart & Vascular CareIf you found this episode helpful, we also recommend:What Your Blood Pressure and Cholesterol Numbers Really MeanCalcium Scores Explained: What Your Heart Rick Really Looks LikeHeart Disease in Young Adults: Why It's Rising (And What to Watch For)

In this episode of The Lead, host Deepak Pasupula, MD, MPH, FHRS, is joined by Zaniar Ghazizadeh, MD, and Pugazhendhi Vijayaraman, MD, FHRS, to discuss the journal article, The Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure (The HeartSync-LBBP Randomized Clinical Trial). Together, they review the long-term outcomes of left bundle-branch pacing compared with biventricular pacing in patients with heart failure and discuss the findings of the HeartSync-LBBP randomized clinical trial. Learning Objectives Review the long-term outcomes of left bundle-branch pacing compared with biventricular pacing in patients with heart failure. Discuss the findings of the HeartSync-LBBP randomized clinical trial. Examine the clinical implications of comparing left bundle-branch pacing with biventricular pacing in heart failure. Host: Deepak Pasupula, MD, MPH, FHRS   Guests: Zaniar Ghazizadeh, MD and Pugazhendhi Vijayaraman, MD, FHRS   Disclosures: D. Pasupula No relevant disclosures   Z. Ghazizadeh No relevant disclosures   P. Vijayaraman Honoraria/Speaking/Consulting Fee: Biotronik, Boston Scientific, Abbott, Medtronic Research: Medtronic Fellowship Support: Medtronic

KYW Newsradio's Rasa Kaye and Deborah Heart and Lung Center Cardiologist Dr. Geurys Rojas-Marte continue their discussion on the breakthroughs in heart failure treatment.

In this episode, Radha Gopalan, MD, Clinical Professor at University of Arizona College of Medicine - Phoenix, discusses an inpatient cardiac prehab and rehab program designed to reduce frailty, improve functional capacity and help patients become eligible for advanced heart failure therapies.

Join Laura Peters, NP, and Meg Fraser, NP, for a discussion of the latest AAHFN scientific statement, developed jointly with the Heart Failure Society of America, on integrative health technologies in heart failure care. The hosts will discuss practical guidance on incorporating digital health tools into heart failure care—shifting from singular devices to coordinated, team-based, and actionable systems of care.

The Center for Disease Control and Prevention (CDC) along with the National Center for Health Statistics (NCHS) jointly announced the agenda of its September 15-16, 2026, Coordination and Maintenance committee meeting.During the live event, the public can view and provide feedback on proposed amendments to the International Classification of Diseases, 10th Edition (ICD-10), Clinical Modification (CM), and the HIPPA-sanctioned diagnosis reporting convention required on most provider claims.Among the challenging subjects expected to be presented during the two-day meeting, include whether ICD-10-CM should transition from Sepsis-2 to Sepsis-3 terminology, amending heart failure terminology to coincide with the Second Universal Definition of Heart Failure, and whether to apply the Society for Cardiovascular Angiography & Interventions (SCAI) staging classification (A, B, C, D, and E) for cardiogenic shock, and other topics submitted by the public.During the live edition of the popular Internet broadcast, Talk Ten Tuesday, James S. Kennedy, MD, president of CDIMD, will provide his perspective on identifying proposals and outline how the public can participate in a meaningful way.The popular weekly Internet broadcast will also feature these additional instantly recognizable panelists, who will report more news during their segments:• POV: Penny Jefferson, Manager of Coding & Clinical Documentation Integrity Services for the University of California-Davis Medical Center, will share her point of view during the broadcast.• CDI Report: Cheryl Ericson will provide an update on all things clinical documentation integrity (CDI).• SDoH Report: Tiffany Ferguson will report on news happening at the intersection of compliance and medical record coding.• The Coding Report: Christine Geiger will report on the latest coding news.• Talk Ten Tuesday News Desk: Timothy Powell, deliver the latest news from the Talk Ten Tuesday News Desk.

Cardiologist and electrophysiologist Dr. Gregory Marcus, chair of the American Heart Association scientific statement writing group, reveals evidence on coffee/caffeine and cardiovascular health. He discusses how earlier assumptions that caffeine triggers arrhythmias are complicated by genetics, individual risk factors, and mostly observational research. Marcus reviews randomized and observational findings: the CRAVE trial showed no increase in premature atrial contractions but more premature ventricular contractions on coffee days; a trial in post-cardioversion patients found less atrial fibrillation with daily coffee. Observational data suggest lower risks of type 2 diabetes, heart attack, stroke, and AFib among coffee drinkers, while heart failure risk may be lower at low intake but higher around 4–5 drinks/day. He cautions against extrapolating benefits to energy drinks, discusses additives like sugar, touches on alcohol, cannabis, Mediterranean/DASH diets, pollution, and evolving AFib treatments, wearables, and pacing/ablation technologies.

(TW ED) My ED Caused Heart Failure & Almost Killed Me w/ Kate Avnaim | The Hopeaholics Podcast #354Kate Avnaim's father was diagnosed with brain cancer when she was just 6 months old. When Kate was 13 they found it had spread through his whole brain. He chose quality time over more rounds of chemo. She was furious at him but she just didn't understand yet. He passed away and her mom was laid off right after, leaving Kate stuck in a permanent feeling that there was nothing in her life she could control. But she found 1 thing she could control and her eating disorder started shortly after. When her mom took her to the doctor, Kate hid it, wore a weighted vest under her clothes to fake the scale. They still knew something was wrong. They couldn't draw blood from her arm. She was diagnosed with bradycardia, a dangerously low heart rate, with fallouts happening in her sleep. Doctors told her mom on the spot: she needs to go to the hospital right now. No going home first. No packing a bag. The average hospital stay for what she had is one to two weeks. Kate was there for 35 days, on complete bed rest. After that, an online recovery program at home for 8 hours a day for about a month.Kate has since picked up training and has fallen in love with helping others see the potential within themselves and to hopefully be symbol of hope for others who are battling the same things she did growing up.National Alliance for Eating Disorders helpline — 1-866-662-1235Follow the Hopeaholics on our Socials:https://www.instagram.com/thehopeaholics https://linktr.ee/thehopeaholicsGo to www.Wolfpak.com today and support our sponsors. Don't forget to use code: HOPEAHOLICSPODCAST for 10% off!Visit our Treatment Centers: https://www.hopebythesea.comIf you or a loved one needs help, please call or text 949-615-8588. We have the resources to treat mental health and addiction. Sponsored by the Infiniti Group LLC:https://www.infinitigroupllc.com Join our patreon to get access to an EXTRA EPISODE every week of ‘Off the Record', exclusive content, a thriving recovery community, and opportunities to be featured on the podcast. https://patreon.com/TheHopeaholics Our Merch: https://thehopeaholics.myshopify.com#TheHopeaholics #redemption #recovery #AlcoholAddiction #AddictionRecovery #wedorecover #SobrietyJourney #MyStory #Hope #wedorecover #treatmentcenter #natalieevamarie06:48 — Dad diagnosed with brain cancer07:53 — Remove the tumor and lose everything, or 7 more years10:43 — The beginning of losing control.11:11 — Mom laid off right after his death15:36 — No prior body image issues17:22 — The eating disorder started17:51 — Wore a weighted vest to fake the scale at the doctor's office18:34 — No blood could be drawn from her arm19:29 — Bradycardia: dangerously low heart rate21:24 — Hating the mirror, isolating from everyone21:44 — 35 days in the hospital22:48 — Online recovery program at home23:13 — Feeling proud of her body for the first time27:05 — ED are addiction. Once you start, you cannot stop29:50 — Screaming at anyone who tried to help.38:07 — Relationship with God39:52 — Got mad at God after dad died50:07 — Eight months recovered52:09 — What would my dad be thinking watching me in the hospital?54:29 — God gave you this body to use56:03 — Exercise as a blessing instead of a punishment1:00:22 — What would you tell someone silently struggling right now?

Each week, join Editor-in-Chief Bradley Maron, along with cohosts Mercedes Carnethon and Jane Wilcox for the new iteration of Circulation on the Run. This week, please join Brad and Mercedes as they first welcome Specialty Associate Editor Mukta Srivastava to discuss the new Circulation article type, Images of Cardiovascular Medicine. Then, Brad and Mercedes talk with Chair and First Author Mary Norine "Minnow" Walsh to discuss the "AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20260817.380420

Interview: Dr. Ozoemena: Welcome back to our community health podcast, where we discuss important health topics in ways everybody can understand. Today we will be talking about Heart Failure. Many people have heard this term before, but it often causes fear and confusion. Here to talk about this important topic is Dr. Ken Nweke, a resident at our program, and he will be discussing this topic in Pidgin English so that some people in our community can understand it. Dr. Nweke, welcome to the program.  Dr. Nweke: Thank you very much. I happy make we discuss dis very important mata today.  Dr. Ozoemena: Let's start with the basics. What exactly is heart failure?  Dr. Nweke: First make we understand one thing. The heart na our generator. Just like generator dey provide light for house, the heart dey pump blood carry oxygen and nutrients go every part of the body. Every organ for body depend on the heart to survive. When person get heart failure, e no mean say the heart don stop work. E mean say the heart no dey pump enough blood and oxygen reach the body the as e suppose. The generator still dey run, but e no get enough power again. That struggle fit make different parts of the body begin show signs say wahala dey.  Dr. Ozoemena: What are some of the common causes of heart failure?  Dr. Nweke: Many things fit cause heart failure. One common cause na high blood pressure wey person don get for long time. If blood pressure high for many years, the heart go dey work harder pass normal every day. After some time, the heart fit begin weak. Heart attack fit also damage the heart muscle. When blood no reach part of the heart muscle, dat part fit damage and the heart no go pump blood well again. Sugar disease wey oyibo dey call diabetes also fit cause am Kidney disease fit contribute too. Some people get heart valve problems. Some oda people fit get heart problems from when dem born dem. People wey dey drink alcohol like water or people wey dey smoke fit develop am. Certain yama yama disease or infections fit affect the heart muscle. And for some families, heart problems fit run from generation to generation.  Dr. Ozoemena: What symptoms should people watch out for?  Dr. Nweke: One big sign na shortness of breath. At first, person fit notice am when e dey walk fast, climb stairs, or do heavy work. As the condition worsen, breathing fit become difficult even when person just dey rest. Some people go wake up for night because dem no fit breathe well. Some people go need plenty pillows before dem fit sleep well. Leg, ankle and foot fit swell. Water fit gather for body. Some people go notice say dem gain weight because water don full for body. Person fit tire easily. Things wey dem fit do before without problem fit become difficult. Some people fit get cough wey no gree go. Others fit notice swelling for belle because fluid don gather. Heart fit dey beat fast or anyhow.  Dr. Ozoemena: When should someone seek medical attention?  Dr. Nweke: If person dey notice shortness of breath wey no dey improve, swelling for leg, tiredness wey no dey normal, cough wey no gree stop, or weight gain wey sudden, e dey very important make e go see doctor. If person suddenly no fit breathe, get serious chest pain, faint, or collapse, dat one fit be emergency. Make dem go hospital immediately.  Dr. Ozoemena: How do doctors find out if someone has heart failure?  Dr. Nweke: Doctor go first ask plenty questions make dem sabi wetin b d kasala - doctors dey call history taking. Doctor go examine the patient. Dem go check blood pressure. Dem fit listen to the heart and lungs with stethoscope. Dem fit check for swelling for leg and foot. Blood tests fit help. Some blood tests fit show whether the heart dey under stress. Chest X-ray fit show whether fluid don gather for the lungs. EKG fit help weda electricals for d heart dey ok. One very important test na echocardiogram. Na ultrasound of the heart. E fit show say d heart don weak as e dey pump blood. e dey also check weda d heart valves dey ok. Heart valves na small small doors wey dey for heart wey dey open or close as the heart dey pump. Sometimes doctor fit request other tests depending on the situation.  Dr. Ozoemena: Can heart failure be treated?  Dr. Nweke: Yes or Better treatment dey. Although some cases no fit cure completely, treatment fit help people make dem live longer and feel better. We get medicines wey fit help the heart work better. Some medicines help remove extra water from the body. Some medicines help reduce the work wey the heart dey do. Others fit help protect the heart make e no weak For some people, doctor fit recommend special devices or surgery depending on the cause. But medicine no be the only thing. Lifestyle changes important too.  Dr. Ozoemena: What lifestyle changes can help?  Dr. Nweke: Person wey get heart failure suppose reduce salt for food. Too much salt fit make water gather for body. Dem suppose take medicines exactly the way doctor prescribe. Regular exercise fit help if doctor say e safe. Make dem avoid smoking. Too much alcohol no good. Try maintain healthy body weight. And make person keep all clinic appointments so doctor fit monitor the condition.  Dr. Ozoemena: Can heart failure be prevented?  Dr. Nweke: For many people, yes. make we control high blood pressure - taking medication, go see your doctor regularly Control sugar disease/diabetes. Make we try dey exercise regularly. Make we dey eat healthy food. Reduce salt for food. Avoid smoking. Avoid too much alcohol. Keep healthy weight. And go for regular medical checkup. Many times, if we control these risk factors early, we fit reduce the chance of developing heart failure. Dr. Ozoemena: Before we close, what would you like everyone listening to remember?  Dr. Nweke: Remember say heart failure no mean say the heart don stop work. The heart still dey work, but e dey struggle. Think of am like generator wey still dey run but im light weak, e no dey carry wetin e dey carry before. If you notice shortness of breath, swelling for leg, unusual tiredness, cough wey no gree go, or sudden weight gain, make you go see doctor. No wait until the condition become serious.  Dr. Ozoemena: Thank you, Dr. Nweke. And thank you to everyone listening today. Remember, heart na our generator. Take care of am. Until next time, stay healthy and stay informed Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!  _____________________ References: Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

Join us as we explore the rapidly evolving world of pediatric heart failure and ventricular assist devices. Through conversations with leading experts, we discuss the latest innovations, emerging research, and real-world challenges while gaining insights into where the field is headed and what the future holds for children with advanced heart failure. Hosts: Chris Knoll, MD (Phoenix Children's) Guests: Christina J. VanderPluym, MD (Boston Children's), Jonathan B. Edelson, MD (Children's Hospital of Philadelphia), Joseph Spinner, MD (Texas Children's) Executive Producer: Chris Knoll, MD (Phoenix Children's) Sponsor: Rady Children's Heart Institute

Heart failure patients are often living in a black box – not knowing how they're really doing until they end up in the ER. StartUp Health community member Sean Matsuoka, CEO & Co-founder of General Prognostics (GPx) ( https://www.startuphealth.com/gpx ...

This week's topics include caffeine's impact on CVD, antihistamines and atopic dermatitis, a community designed diet for heart failure, and e-cigarettes after smoking cessation.

Recorded at EHRA 2026, this episode of The Lead features host Melissa Middeldorp, MPH, PhD, FHRS, in conversation with Sana Al-Khatib, MD, MHS, FHRS, and Wei Hua, MD, FHRS, about the journal article, Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial. Together, they discuss the findings of the PhysioSync-HF randomized clinical trial, comparing conduction system pacing with biventricular pacing in patients with heart failure and exploring the potential implications for clinical practice.   Learning Objectives: Review the design and key findings of the PhysioSync-HF randomized clinical trial comparing conduction system pacing and biventricular pacing in patients with heart failure. Discuss the differences between conduction system pacing and biventricular pacing as evaluated in the PhysioSync-HF trial. Examine the potential clinical implications of the trial findings for pacing strategies in patients with heart failure.   Host: Melissa Middeldorp, MPH, PhD, FHRS Guests: Sana Al-Khatib, MD, MHS, FHRS and Wei Hua, MD, FHRS   Disclosures: M. Middeldorp ·      No relevant disclosures   S. Al-Khatib ·      Other Financial Relationship: American Heart Association   W. Hua ·      No relevant disclosures

Commentary by Dr. Cheng Liu.

KYW Newsradio's Rasa Kaye and Deborah Heart and Lung Center Cardiologist Dr. Geurys Rojas-Marte discuss the breakthroughs in heart failure treatment.

Heart failure remains one of the leading causes of hospitalization among older adults worldwide. During episodes of acute decompensated heart failure (ADHF), excess fluid builds up in the lungs and body, making breathing difficult and increasing the risk of serious complications. Although intravenous loop diuretics such as furosemide are the standard treatment for relieving congestion, many patients continue to experience persistent inflammation, ongoing cardiac remodeling, and worsening heart function despite therapy. A research paper published in Volume 18 of Aging titled “Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF),” investigated whether combining intravenous furosemide with small volumes of hypertonic saline solution (HSS) could improve biological markers associated with heart failure compared with furosemide alone. Full blog post - https://aging-us.org/2026/08/hypertonic-saline-plus-furosemide-improves-heart-failure-biomarkers-in-randomized-trial/ DOI - https://doi.org/10.18632/aging.206364 Corresponding author - Antonino Tuttolomondo - bruno.tuttolomondo@unipa.it Abstract video - https://www.youtube.com/watch?v=EG65XlcDJ3U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206364 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, heart failure, acute decompensated heart failure, furosemide, hypertonic saline solution To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In 11,409 adults with CKD and no prior heart failure, three standard ECG features independently predicted new-onset HF hospitalization. The findings support routine ECG as a low-cost adjunct to existing HF risk assessment in CKD.

CardioNerds Dr. Rohit Nathani, Dr. Atefeh Ghorbanzadeh, and Dr. Mariam Riad, discuss Obesity-related Heart Failure with Preserved Ejection Fraction (HFpEF) with Dr. John Ostrominski.  This episode was produced as part of the CardioNerds Academy curriculum by House Jones under the guidance of House Chief, Dr. Mariam Riad and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This episode highlights the diverse clinical phenotypes and complex, multifaceted pathophysiology of HFpEF. We take a deep dive into the therapeutic advances that represent paradigm shift in metabolic modulation aimed at improving outcomes in patients with HFpEF and metabolic syndrome. Audio editing by CardioNerds intern Pacey Wetstein. Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls HFpEF is a constellation of symptoms often with different underlying pathophenotypes; cardiometabolic type is rising in incidence. Diagnosis is predominantly based on the clinical scenario along with supporting evidence from imaging modalities such as echocardiogram, cardiac MRI, and right heart catheterization. Cardiometabolic HFpEF is a complex syndrome characterized by dysregulated lipid metabolism, systemic inflammation, and hemodynamic abnormalities, all of which contribute to exercise intolerance and frailty. Lifestyle interventions, comorbidities management, and HFpEF therapeutics go hand in hand for comprehensive HFpEF care and offer opportunities for multispecialty collaboration to achieve optimal patient outcomes. References Ostrominski, J, Højbjerg Lassen, M, Butt, J. et al. Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. JACC. 2025 Nov, 86 (20) 1760–1777.https://doi.org/10.1016/j.jacc.2025.08.012  Packer, M. The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. JACC. 2025 Oct, 86 (16) 1269–1373.https://doi.org/10.1016/j.jacc.2025.06.055 Ahmed, N., Dalmasso, C., Turner, M.B. et al. From fat to filter: the effect of adipose tissue-derived signals on kidney function. Nat Rev Nephrol 21, 417–434 (2025). https://doi.org/10.1038/s41581-025-00950-5 Alicic, R.Z., Neumiller, J.J. & Tuttle, K.R. GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease. Nat Rev Nephrol 22, 265–282 (2026). https://doi.org/10.1038/s41581-025-01036-y Ostrominski, J, Harrington, J, Claggett, B. et al. Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. JACC. 2025 Nov, 86 (20) 1781–1801.https://doi.org/10.1016/j.jacc.2025.08.039

Interview with Lauren A. Eberly, MD, MPH author of MUTTON -HF (Medically Utilized Tailored Traditional foods to Optimize Nutrition in Heart Failure): A Randomized Trial of an Indigenous Food is Medicine Intervention and Kurt Hager, MD author of Medically Tailored Meals and Heart Failure: A New Benchmark in Care. Hosted by Eve Rittenberg, MD Related Content: An Indigenous Food Is Medicine Intervention Lessons From a Community-Designed Meal Program for Heart Failure

Interview with Lauren A. Eberly, MD, MPH author of MUTTON -HF (Medically Utilized Tailored Traditional foods to Optimize Nutrition in Heart Failure): A Randomized Trial of an Indigenous Food is Medicine Intervention and Kurt Hager, MD author of Medically Tailored Meals and Heart Failure: A New Benchmark in Care. Hosted by Eve Rittenberg, MD Related Content: An Indigenous Food Is Medicine Intervention Lessons From a Community-Designed Meal Program for Heart Failure

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Gain expert insights on how best to implement GDMT for your patients in the transition from hospitalization to post-discharge. Credit available for this activity expires: 7/22/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/when-and-how-should-i-optimize-heart-failure-treatments-my-2026a1000ngg?ecd=bdc_podcast_libsyn_mscpedu

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

DAPT back in the news, a practice-changing trial in VTE therapy, new knowledge in sudden cardiac death, heart failure definitions updated, and a dumb decision by NICE in the UK are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Antiplatelet Therapy After Stenting DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588 HOST-EXAM Trial at 2 years https://pubmed.ncbi.nlm.nih.gov/34010616/ HOST-EXAM Trial at 10 years 10.1016/S0140-6736(26)00422-8 External Link Nick Kurzen on X https://x.com/ncurzen/status/2077676739463922151 II Aspirin Proves Its Mettle After Hip and Knee Replacement EPCAT III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2603649 CRISTAL Trial https://jamanetwork.com/journals/jama/fullarticle/2795528 III New (and old) Knowledge in Sudden Cardiac Death Sudden Cardiac Death and its Relation to Cardiac Disease at Autopsy https://doi.org/10.1016/j.jacc.2026.01.029 Sudden Cardiac Death Due to MI With Obstructive and Nonobstructive Coronary Arteries https://doi.org/10.1016/j.jacc.2026.01.030 Frequency of Sudden Cardiac Death and Profiles of Risk https://www.ajconline.org/article/S0002-9149(97)00477-3/fulltext IV Heart Failure Diagnosis AHA/ACC/ESC/WHF Expert Consensus Document http://jacc.org/doi/10.1016/j.jacc.2026.05.036 V NICE Makes a Dumb Decision NICE Recommends New Nonsteroidal MRA for Heart Failure https://www.medscape.com/viewarticle/nice-recommends-new-nonsteroidal-mra-heart-failure-2026a1000nzv You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this episode, Faraz Ahmad, MD, Associate Director at the Center for Artificial Intelligence, and Jonathan Hourmozdi, MD, Heart Failure and Heart Transplantation at Northwestern Medicine Bluhm Cardiovascular Institute, discuss how AI is improving heart failure diagnosis, care delivery, and patient engagement while emphasizing the importance of responsible implementation and governance. They also share their vision for an AI-powered future that reduces administrative burden, strengthens clinician-patient relationships, and expands access to high-quality cardiovascular care.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Dr. Quentin R. Youmans, Heart Failure and Heart Transplant Cardiologist, Northwestern Medicine, joins John Williams to talk about heart health, why he encourages patients to start small when on the path to better heart health, why it’s important to bring heart health screenings into the community, what you should know about the early signs of […]

Dr. Quentin R. Youmans, Heart Failure and Heart Transplant Cardiologist, Northwestern Medicine, joins John Williams to talk about heart health, why he encourages patients to start small when on the path to better heart health, why it’s important to bring heart health screenings into the community, what you should know about the early signs of […]

Dr. Quentin R. Youmans, Heart Failure and Heart Transplant Cardiologist, Northwestern Medicine, joins John Williams to talk about heart health, why he encourages patients to start small when on the path to better heart health, why it’s important to bring heart health screenings into the community, what you should know about the early signs of […]

❤️ New JACC statement, big clinical reset: the 2026 Second Universal Definition of Heart Failure moves us beyond rigid EF cutoffs toward a more useful bedside framework—define the syndrome, identify the stage, seek the cause, respect geography and social context, and follow the trajectory. The key message: improved EF is not "cured HF," and pre-HF is a prevention window hiding in plain sight. For clinicians: less "What's the EF?" and more "What's the cause, stage, trajectory, and context?"

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

──────────────────────────────────────── [00:05:00] Hegseth Quotes Psalm 144 as God's Blessing for War — Knight: David Prayed Before Every Battle and Never Assumed God Was With Him David used the Urim and Thummim to ask God's will before war. Hegseth has no such instrument and no declaration of war from God or Congress. ──────────────────────────────────────── [00:15:00] Dispensationalism's Core Error: Treating the Shadow as Greater Than the Reality It Points To Knight: Hebrews was written to people returning to the shadow of Judaism rather than the substance in Christ — Hegseth and Huckabee are the Judaizers of Galatians, replacing Christ with a political state. ──────────────────────────────────────── [00:28:00] Nick Kupper: The COVID Shot Was Never Legally Approved — Pfizer Didn't Manufacture an Approved Version Until January 2022 DOD admitted in Kupper's lawsuit that nothing was fully approved until June 2022 — by which time the Air Force had already kicked people out for the unlawfully mandated product. ──────────────────────────────────────── [00:38:00] Kupper's Base Immunologist Admitted He Had More Antibodies Than the Vaccinated — His Religious Accommodation Was Denied Anyway Kupper had natural immunity; his immunologist confirmed he had more antibodies than someone with both shots. Every single religious accommodation filed was denied. ──────────────────────────────────────── [00:50:00] Kupper Was Given Separation Papers Three Weeks Before His 19-Year Mark — One Year Short of a Full Retirement A class-wide court injunction from attorney Aaron Siri covered Kupper the day after his separation papers arrived — but thousands of others had no such protection. ──────────────────────────────────────── [01:02:00] $6 Billion Was Already Appropriated to These Service Members — the Military Used It for Something Else When It Kicked Them Out Kupper: every dollar was authorized in the NDAA but never spent on the personnel allocated — it could be repaid to the 8,000 dismissed without any new appropriation. ──────────────────────────────────────── [01:12:00] A Technical Sergeant With Both Shots Died of Heart Failure in His Early 30s — the Air Force Stopped Updating Its COVID Death Tracker That Day The Air Force had listed 16 COVID deaths noting none were vaccinated — the day this man died with both shots on record, they stopped updating the tracker. ──────────────────────────────────────── [01:22:00] 'Duty to Disobey' Documentary Releases in AMC Theaters June 30 — dutytodisobeyfilm.com Children's Health Defense produced this with service members from multiple branches; Ron Johnson appears alongside those kicked out for refusing the unlawful emergency use mandate. ──────────────────────────────────────── [01:38:00] Dr. Michael Guillén: 95% of the Universe Is Invisible — Modern Cosmology Has Been in Crisis Since Hubble's Discovery in 1929 Dark matter and dark energy are completely unknown. The steady-state model was destroyed by Hubble's discovery that the universe is expanding — the crisis has deepened since. ──────────────────────────────────────── [01:55:00] Guillén: From Atheist to Christian Through Science — the Universe Had to Hit the Jackpot a Million Times at Every Level for Us to Exist The anthropic principle: from the quantum level to the cosmic web, everything was calibrated precisely for life — either infinite accidents or one designer. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

──────────────────────────────────────── [00:05:00] Hegseth Quotes Psalm 144 as God's Blessing for War — Knight: David Prayed Before Every Battle and Never Assumed God Was With Him David used the Urim and Thummim to ask God's will before war. Hegseth has no such instrument and no declaration of war from God or Congress. ──────────────────────────────────────── [00:15:00] Dispensationalism's Core Error: Treating the Shadow as Greater Than the Reality It Points To Knight: Hebrews was written to people returning to the shadow of Judaism rather than the substance in Christ — Hegseth and Huckabee are the Judaizers of Galatians, replacing Christ with a political state. ──────────────────────────────────────── [00:28:00] Nick Kupper: The COVID Shot Was Never Legally Approved — Pfizer Didn't Manufacture an Approved Version Until January 2022 DOD admitted in Kupper's lawsuit that nothing was fully approved until June 2022 — by which time the Air Force had already kicked people out for the unlawfully mandated product. ──────────────────────────────────────── [00:38:00] Kupper's Base Immunologist Admitted He Had More Antibodies Than the Vaccinated — His Religious Accommodation Was Denied Anyway Kupper had natural immunity; his immunologist confirmed he had more antibodies than someone with both shots. Every single religious accommodation filed was denied. ──────────────────────────────────────── [00:50:00] Kupper Was Given Separation Papers Three Weeks Before His 19-Year Mark — One Year Short of a Full Retirement A class-wide court injunction from attorney Aaron Siri covered Kupper the day after his separation papers arrived — but thousands of others had no such protection. ──────────────────────────────────────── [01:02:00] $6 Billion Was Already Appropriated to These Service Members — the Military Used It for Something Else When It Kicked Them Out Kupper: every dollar was authorized in the NDAA but never spent on the personnel allocated — it could be repaid to the 8,000 dismissed without any new appropriation. ──────────────────────────────────────── [01:12:00] A Technical Sergeant With Both Shots Died of Heart Failure in His Early 30s — the Air Force Stopped Updating Its COVID Death Tracker That Day The Air Force had listed 16 COVID deaths noting none were vaccinated — the day this man died with both shots on record, they stopped updating the tracker. ──────────────────────────────────────── [01:22:00] 'Duty to Disobey' Documentary Releases in AMC Theaters June 30 — dutytodisobeyfilm.com Children's Health Defense produced this with service members from multiple branches; Ron Johnson appears alongside those kicked out for refusing the unlawful emergency use mandate. ──────────────────────────────────────── [01:38:00] Dr. Michael Guillén: 95% of the Universe Is Invisible — Modern Cosmology Has Been in Crisis Since Hubble's Discovery in 1929 Dark matter and dark energy are completely unknown. The steady-state model was destroyed by Hubble's discovery that the universe is expanding — the crisis has deepened since. ──────────────────────────────────────── [01:55:00] Guillén: From Atheist to Christian Through Science — the Universe Had to Hit the Jackpot a Million Times at Every Level for Us to Exist The anthropic principle: from the quantum level to the cosmic web, everything was calibrated precisely for life — either infinite accidents or one designer. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

In this episode, Jeffrey Farber, MD, President & CEO of The New Jewish Home, discusses the organization's accredited heart failure program within a skilled nursing facility setting. He shares how specialized cardiac rehabilitation, interdisciplinary care, and close partnerships with academic medical centers are helping medically complex older adults recover safely and regain quality of life after hospitalization.

SEASON 4 EPISODE 84: COUNTDOWN WITH KEITH OLBERMANN A-Block (3:00) SPECIAL COMMENT: Back from a week off just in time to put the podcast on health hiatus...details within today's supersized edition. Plus, befitting the time off, some meta pictures on how Democrats should plan for what they want this country to look like on its 300th anniversary, if it lasts that long. Will we have jailed Trump and gotten back the money he took? Undone his damage? Eliminated the anachronistic idea that Wyoming should have as many senators as California? Let the Supreme Court continue to lie, cheat and steal the democracy from under us? As John Candy said in "Splash": Think big, be big, my friend. MORE IMMEDIATELY: Whaddya mean the Governor of Virginia hasn't been BRIEFED on the way to overturn her state's Supreme Court's usurpation of redistricting? Why the hell not Hakeem Jeffries? Anybody notice Trump is simply rotating the same three lies about Iran? Why are only independent journalists like Garrett Graff still covering the WHCD non-shooting when the New York Times is doing 31 paragraphs on the future of the dinner like anybody gave a crap? AND MOST IMPORTANTLY: stop saying Trump is painting everything GOLD. That color is not GOLD. It is the color of WEE WEE. Say it. Use the clinical terms, use the gutter terms. The gutter terms define this idiot president. Stop saying gold when you mean whizzzzzzzzzzzzzz. B-Block (56:00) ON THE PASSING OF TED TURNER: Hard to believe few of the obituaries mentioned how he also invented 7-day-a-week sports on national television. Or how Jane Fonda kept him from destroying himself in, like, 1982. One particularly harrowing saga had him telling the lowest ranking staffer at CNN's Washington Bureau which way, when he finally decided he'd do it, he'd do it. And this is said with admiration and affection for the man who created the place where I and so many of the figures of the last 45 years began our TV careers. C-Block (1:30:00) ALL TED ALL THE TIME: I was holding back until I was certain I wouldn't jinx him. My beloved first rescue dog, Ted, was up against it last fall. I took him to the University of Florida for life-saving open heart surgery and boy, did they! Eight hours on the table, eight hours of SICU, all for an eight pound dog and now - he's not even on any medications! It's a long story and I would insist it's worth hearing it. And if you have a dog (or know of one) moving from Mitral Valve Disease to Heart Failure, maybe this will provide you with hope - and an option.See omnystudio.com/listener for privacy information.

What if one of the most common escalation strategies for acute heart failure doesn't actually improve outcomes? Internal medicine physicians Benjamin P. Geisler, Jeffrey L. Greenwald, and Kathy May Tran, editors of 50 Studies Every Hospitalist Should Know, join the show to break down what the DOSE trial really tells us about managing diuretics on the wards. Based on their KevinMD article "Managing acute heart failure: evidence from the DOSE trial," they explain why continuous furosemide infusions showed no clinical advantage over intermittent boluses for decongestion, and what that means for your daily practice. You will hear how headline-driven medicine can mislead clinicians, why knowing who was excluded from a trial matters as much as the results, and how evidence-based medicine teaching is evolving in the age of AI. Whether you are a hospitalist, a trainee on the wards, or a primary care physician managing heart failure transitions, this episode will sharpen how you read and apply the studies that shape patient care. Tune into our episode "2026 Cholesterol Guidelines: LDL goals, lipoprotein(a), and coronary calcium scoring," brought to you by Novartis Pharmaceuticals Corporation. For the first time in eight years, LDL cholesterol goals have changed, and preventive cardiologist Seth Baum says the new guidelines are a long-overdue course correction. He breaks down the new LDL targets for your highest-risk patients, why the LDL hypothesis should be retired in favor of the LDL fact, why lipoprotein(a) screening finally belongs in every patient's workup, what a coronary calcium score over 300 really means for how aggressively you treat, and how to talk to statin-skeptical patients without losing their trust. Listen now at KevinMD.com/cholesterol. VISIT SPONSOR → https://kevinmd.com/cholesterol Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended